- Home
- SPE vs OBIO Comparison
SPE vs OBIO Comparison
Compare SPE & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPE
- OBIO
- Stock Information
- Founded
- SPE 1993
- OBIO 2017
- Country
- SPE United States
- OBIO United States
- Employees
- SPE N/A
- OBIO N/A
- Industry
- SPE Finance/Investors Services
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SPE Finance
- OBIO Health Care
- Exchange
- SPE Nasdaq
- OBIO Nasdaq
- Market Cap
- SPE 166.0M
- OBIO 172.1M
- IPO Year
- SPE N/A
- OBIO N/A
- Fundamental
- Price
- SPE $15.18
- OBIO $3.81
- Analyst Decision
- SPE
- OBIO Strong Buy
- Analyst Count
- SPE 0
- OBIO 4
- Target Price
- SPE N/A
- OBIO $14.00
- AVG Volume (30 Days)
- SPE 25.4K
- OBIO 335.2K
- Earning Date
- SPE 01-01-0001
- OBIO 11-12-2025
- Dividend Yield
- SPE 8.55%
- OBIO N/A
- EPS Growth
- SPE N/A
- OBIO N/A
- EPS
- SPE N/A
- OBIO N/A
- Revenue
- SPE N/A
- OBIO $2,944,000.00
- Revenue This Year
- SPE N/A
- OBIO $31.43
- Revenue Next Year
- SPE N/A
- OBIO $10.87
- P/E Ratio
- SPE N/A
- OBIO N/A
- Revenue Growth
- SPE N/A
- OBIO 41.61
- 52 Week Low
- SPE $10.26
- OBIO $2.20
- 52 Week High
- SPE $12.59
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- SPE 42.93
- OBIO 56.85
- Support Level
- SPE $15.14
- OBIO $3.67
- Resistance Level
- SPE $15.50
- OBIO $4.02
- Average True Range (ATR)
- SPE 0.19
- OBIO 0.30
- MACD
- SPE -0.01
- OBIO -0.03
- Stochastic Oscillator
- SPE 20.82
- OBIO 53.17
About SPE Special Opportunities Fund Inc
Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.